Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vx-702. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 12/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 4/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | MAPK9 | P45984 | 2/20 | 1.00 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 1.00 |
| ▸ | MAPK10 | P53779 | 1/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 1/20 | 1.00 |
| ▸ | ACVR2B | Q13705 | 1/20 | 1.00 |
| ▸ | MYLK | Q15746 | 1/20 | 1.00 |
| ▸ | NLK | Q9UBE8 | 1/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vx-702 SCHEMBL29367579 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11PRKD2PRKD3MAPK9 | |
| Vx-702 SCHEMBL29394821 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11PRKD2PRKD3MAPK9 | |
| Vx-702 SCHEMBL29352789 | 1.00 | MAPK14 (1.00) | MAPK14MAPK11PRKD2PRKD3MAPK9 | |
| SCHEMBL22764068 | 0.93 | MAPK14 (0.86) | MAPK14MAPK11PRKD2PRKD3MAPK9 | |
| SCHEMBL14225410 | 0.89 | MAPK14 (0.80) | MAPK14MAPK11PRKD2PRKD3MAPK9 | |
| SCHEMBL21952140 | 0.88 | MAPK14 (0.79) | MAPK14MAPK11PRKD2PRKD3MAPK9 | |
| SCHEMBL12582971 | 0.86 | MAPK14 (0.74) | MAPK14MAPK11PRKD2PRKD3MAPK9 | |
| SCHEMBL12712568 | 0.86 | MAPK14 (0.74) | MAPK14MAPK11PRKD2PRKD3MAPK9 | |
| SCHEMBL13907257 | 0.84 | MAPK14 (0.73) | MAPK14MAPK11PRKD2PRKD3MAPK9 | |
| SCHEMBL13907271 | 0.84 | MAPK14 (0.73) | MAPK14MAPK11PRKD2PRKD3MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 339 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| US-20200237728-A1 | CHEMOTHERAPEUTIC METHODS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2020-07-30 | — | — | US | claimed |
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | claimed |
| US-9598675-B2 | Method for preparing mesenchymal stem cell-like cells and cardiomyocyte-like cells | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2017-03-21 | — | — | US | claimed |
| US-20160331736-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2016-11-17 | — | — | US | claimed |
| EP-3069732-A1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | The Doshisha (JP) | 2016-09-21 | — | — | EP | claimed |
| US-20160135446-A1 | CELL STABILIZATION | MXCGLOBAL INC. | 2016-05-19 | — | — | US | claimed |
| US-20150284683-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2015-10-08 | — | — | US | claimed |
| EP-2882848-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | Singapore Health Services Pte Ltd (SG) | 2015-06-17 | — | — | EP | claimed |
| US-20140314725-A1 | METHOD FOR PREPARING MESENCHYMAL STEM CELL-LIKE CELLS AND CARDIOMYOCYTE-LIKE CELLS | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2014-10-23 | — | — | US | claimed |
| WO-2014122298-A1 | INTERLEUKIN-4 INHIBITORS FOR THE TREAMTENT OF NEUTROPENIA | Universität Zürich (CH) | 2014-08-14 | — | — | WO | claimed |
| WO-2014025315-A1 | METHOD, COMBINATION AND/OR COMPOSITION FOR INDUCING CARDIOMYOCYTE DIFFERENTATION | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2014-02-13 | — | — | WO | claimed |
| WO-2013055297-A1 | METHOD FOR PREPARING MESENCHYMAL STEM CELL-LIKE CELLS AND CARDIOMYOCYTE-LIKE CELLS | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2013-04-18 | — | — | WO | claimed |
| EP-2396303-A2 | SOLID FORMS OF 2-(2, 4-DIFLUOROPHENYL)-6-(1-(2,6-DIFLUOROPHENYL)UREIDO)NICOTINAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2011-12-21 | — | — | EP | claimed |
| US-20110086891-A1 | Solid Forms of 2-(2,4-Difluorophenyl)-6-(1-(2,6-Difluorophenyl)Ureido)Nicotinamide) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-14 | — | — | US | claimed |
| WO-2010093889-A2 | SOLID FORMS OF 2-(2, 4-DIFLUOROPHENYL)-6-(1-(2,6-DIFLUOROPHENYL)UREIDO)NICOTINAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-19 | — | — | WO | claimed |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | POOLBEG PHARMA UK LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| US-20070173649-A1 | Processes for the facile synthesis of diaryl amines and analogues thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885MAPK11 26/4885PRKD2 2029/4885 |
| US-20160135446-A1 | CELL STABILIZATION | CALR, CALU, TREH | MAPK14 4288/4885MAPK11 4639/4885PRKD2 1991/4885 |
| US-20110086891-A1 | Solid Forms of 2-(2,4-Difluorophenyl)-6-(1-(2,6-Difluorophenyl)Ureido)Nicotinamide) | NNT, NAMPT, NNMT | MAPK14 4648/4885MAPK11 4444/4885PRKD2 2161/4885 |
| US-20260115177-A1 | MEDICINAL PRODUCTS AND METHODS FOR THE ALLEVIATION OF CANCER IMMUNOTHERA-PY-ASSOCIATED CYTOKINE RELEASE SYNDROME | MAPK13, MAPK11, MAPK1 | MAPK14 18/4885MAPK11 2/4885PRKD2 1327/4885 |
| US-20070173649-A1 | Processes for the facile synthesis of diaryl amines and analogues thereof | ABL1, PNMT, MAOA | MAPK14 2440/4885MAPK11 1780/4885PRKD2 2986/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885MAPK11 24/4885PRKD2 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.